Vyome Biosciences announces top-line results from Phase 1 study of VB-1953 for patients with facial…
Treatment with VB-1953 resulted in a reduction of inflammatory and non-inflammatory lesions and in IGA scores
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.